Glenmark Pharmaceuticals Ltd. appears to have stolen a march over its peers after it received regulatory clearance in India for its version of favipiravir, the antiviral currently being evaluated as part of treatment options for COVID-19 in several countries including Japan.
Glenmark’s product, to be sold as FabiFlu, has received emergency use authorization in India for the treatment of mild to...







